Cargando…
Healthy Volunteer Studies in the Development of Anticancer Drugs with Genotoxic Findings
BACKGROUND: Recent scientific advances in cancer research have led to the development of immunomodulatory and molecularly targeted drugs with better safety profiles than chemotherapeutics, which makes it possible to include healthy volunteers (HVs) in clinical trials. In this study, we aimed to iden...
Autores principales: | Omes-Smit, Grace, Garsen, Marjolein, Zwiers, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688384/ https://www.ncbi.nlm.nih.gov/pubmed/34379306 http://dx.doi.org/10.1007/s43441-021-00330-8 |
Ejemplares similares
-
Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
por: Demirci, Ebru, et al.
Publicado: (2023) -
A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines
por: Garsen, Marjolein, et al.
Publicado: (2021) -
Reviewing the role of healthy volunteer studies in drug development
por: Karakunnel, Joyson J., et al.
Publicado: (2018) -
Phase I clinical trials of anticancer drugs in healthy volunteers: Need for critical consideration
por: Gupta, Pooja, et al.
Publicado: (2012) -
Healthy volunteers in first‐in‐human oncology drug development for small molecules
por: de las Heras, Begoña, et al.
Publicado: (2021)